Fig. 11From: Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysisEffect of roflumilast vs. placebo on incidence of adverse events. CI, confidence interval; M.-H., Mantel-HaenszelBack to article page